Drug intelligence / Profile preview

fluometacyl

Development stage: Preclinical
Lead developer: CM4CURE
Modality: Small Molecules
Administration: Intravenous

Overview

Fluometacyl is a small molecule, dual-action antimicrobial and antithrombotic agent being developed by CM4CURE. Described as a metabolite of an FDA-approved drug, it leverages existing toxicology data to streamline its clinical development path. The drug is specifically intended for the prevention and treatment of intravenous (IV) catheter-related bloodstream infections (CRBSI) and catheter-related thrombosis (CRT). By combining antimicrobial and antithrombotic properties into a single active pharmaceutical ingredient (API), Fluometacyl aims to address the two most significant complications associated with central venous access, potentially improving patient outcomes and reducing healthcare costs associated with catheter failure.

Brand names: Fluometacyl
Other names: Fluometacyl

Beyond the preview

Go deeper on fluometacyl.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluometacyl.

Explore the full profile